Instead of diversifying across diseases, Kenai is building deep expertise in Parkinson's. Its pipeline addresses different patient needs: replacing lost cells (lead program), repairing existing damaged cells (002), and targeting inherited forms (003), creating a comprehensive disease franchise.

Despite a recent Phase 2 failure, the LARC2 kinase target for Parkinson's is gaining renewed interest. The strategy is to move beyond "all-comer" trials to focus on patients with specific genetic variants or similar genetic profiles identified through SNPs, expanding the potential patient pool from less than 5% to around 30%.

Prior therapeutic strategies were flawed. Symptomatic treatments squeeze more function from the few remaining neurons until they also die. Disease-modifying drugs, like antibodies, are often ineffective because the blood-brain barrier allows less than 0.1% to reach the brain.

To secure investment in the high-risk neurodegeneration space, companies must avoid significant 'leaps of faith.' A key de-risking factor is applying novel modalities to clinically validated pathways. This provides a stronger scientific foundation than pursuing a completely unproven biological hypothesis, making the venture more compelling to investors.

The next wave of neuroscience therapeutics is shifting from managing broad symptoms (e.g., in autism) to precision therapies. By identifying genetic underpinnings of a disease, developers can create drugs that target the specific biology of patient subpopulations, aiming for disease modification rather than just symptomatic relief.

Instead of focusing on symptomatic relief, Gain Therapeutics' molecule corrects a misfolded enzyme. This restores the enzyme's ability to break down toxic lipids that accumulate in nerve cells, addressing a root cause of cell damage and disease progression, rather than just managing symptoms like dopamine loss.

While designed for the 10% of Parkinson's patients with a specific genetic variant, Gain Therapeutics' trial data shows its drug may benefit a larger group. About 50% of patients without the gene defect also have the toxic lipid buildup the drug targets, suggesting a significantly expanded potential market beyond the initial niche population.

New single-cell atlases of Parkinson's brains show that biological pathways are activated differently depending on the brain region and disease stage. This adds a critical layer of complexity, implying that a "disease-modifying" drug may need to be targeted to specific cell types at specific times, complicating clinical development.

The company's strategic goal is not a cure but to slow the underlying progression of Parkinson's. By reducing toxic lipids and protecting neurons, the aim is to decelerate the disease's advancement so significantly that patients can effectively outlive its most severe impacts. This reframes the value proposition for a neurodegenerative disease.